MX2019013279A - Metodos de tratamiento del sindrome de doose utilizando fenfluramina. - Google Patents

Metodos de tratamiento del sindrome de doose utilizando fenfluramina.

Info

Publication number
MX2019013279A
MX2019013279A MX2019013279A MX2019013279A MX2019013279A MX 2019013279 A MX2019013279 A MX 2019013279A MX 2019013279 A MX2019013279 A MX 2019013279A MX 2019013279 A MX2019013279 A MX 2019013279A MX 2019013279 A MX2019013279 A MX 2019013279A
Authority
MX
Mexico
Prior art keywords
doose syndrome
fenfluramine
treating
methods
patient
Prior art date
Application number
MX2019013279A
Other languages
English (en)
Inventor
Boyd Brooks
J Farr Stephen
Galer Bradley
Original Assignee
Zogenix International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zogenix International Ltd filed Critical Zogenix International Ltd
Publication of MX2019013279A publication Critical patent/MX2019013279A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Un método para tratar y/o prevenir los síntomas del síndrome de Doose en un paciente tal como un paciente diagnosticado previamente con el síndrome de Doose, administrando una dosis efectiva de fenfluramina o su sal farmacéuticamente aceptable a ese paciente. Los pacientes con síndrome de Doose se tratan con una dosis preferida de menos de aproximadamente 10.0 a aproximadamente 0.01 mg/kg/día.
MX2019013279A 2017-05-09 2018-05-04 Metodos de tratamiento del sindrome de doose utilizando fenfluramina. MX2019013279A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762503638P 2017-05-09 2017-05-09
US201762581375P 2017-11-03 2017-11-03
PCT/GB2018/051210 WO2018206924A1 (en) 2017-05-09 2018-05-04 Methods of treating doose syndrome using fenfluramine

Publications (1)

Publication Number Publication Date
MX2019013279A true MX2019013279A (es) 2020-01-15

Family

ID=62148410

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013279A MX2019013279A (es) 2017-05-09 2018-05-04 Metodos de tratamiento del sindrome de doose utilizando fenfluramina.

Country Status (12)

Country Link
US (2) US20200170965A1 (es)
EP (1) EP3634392A1 (es)
JP (2) JP2020519594A (es)
KR (1) KR20190142364A (es)
CN (1) CN110891558A (es)
AU (1) AU2018265353A1 (es)
BR (1) BR112019023483A2 (es)
CA (1) CA3062247A1 (es)
MX (1) MX2019013279A (es)
TW (1) TW201900158A (es)
WO (1) WO2018206924A1 (es)
ZA (1) ZA201907168B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
WO2017060731A1 (en) 2015-10-09 2017-04-13 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
EP3390636B1 (en) 2015-12-14 2021-05-19 Cold Spring Harbor Laboratory Antisense oligomers for treatment of dravet syndrome
US20170174614A1 (en) 2015-12-22 2017-06-22 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
DK3393655T3 (da) 2015-12-22 2021-03-15 Zogenix International Ltd Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
MX2019001799A (es) 2016-08-24 2019-06-13 Zogenix International Ltd Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
PT3673080T (pt) 2017-08-25 2023-12-06 Stoke Therapeutics Inc Oligómeros anti-sentido para o tratamento de estados patológicos e outras doenças
US10682317B2 (en) * 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
JP2021526507A (ja) 2018-05-11 2021-10-07 ゾゲニクス インターナショナル リミテッド 発作により誘発される突然死を処置するための組成物および方法
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
IL298063A (en) 2020-05-11 2023-01-01 Stoke Therapeutics Inc opa1 antisense oligomers for the treatment of conditions and diseases
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
AU2009279372A1 (en) * 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
CA2993665C (en) * 2015-08-24 2023-03-07 Zogenix International Limited Methods of treating lennox-gastaut syndrome using fenfluramine

Also Published As

Publication number Publication date
RU2019135674A3 (es) 2021-08-31
US20220226262A1 (en) 2022-07-21
EP3634392A1 (en) 2020-04-15
CA3062247A1 (en) 2018-11-15
ZA201907168B (en) 2021-01-27
RU2019135674A (ru) 2021-06-09
JP2020519594A (ja) 2020-07-02
WO2018206924A1 (en) 2018-11-15
TW201900158A (zh) 2019-01-01
JP2023071832A (ja) 2023-05-23
US20200170965A1 (en) 2020-06-04
AU2018265353A1 (en) 2019-11-21
KR20190142364A (ko) 2019-12-26
CN110891558A (zh) 2020-03-17
BR112019023483A2 (pt) 2020-06-30

Similar Documents

Publication Publication Date Title
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
WO2019067405A3 (en) FORMULATION OF FENFLURAMINE COMPATIBLE WITH A CÉTOGENEOUS REGIMEN
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2021002321A (es) Nuevos metodos.
MX2016009231A (es) Administracion de tasimelteon en condiciones de ayuno.
AU2024201828A1 (en) Methods of treating and/or preventing actinic keratosis
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2021002322A (es) Nuevos metodos.
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
MX2022004785A (es) Metodos y composiciones para el tratamiento del sindrome de rett.